Targeting the androgen receptor in triple-negative breast cancer: current perspectives

References

• American Cancer SocietyCancer Facts and Figures 2017Atlanta, GAAmerican Cancer Society2017
   Google Scholar
• DentRTrudeauMPritchardKITriple-negative breast cancer: clinical features and patterns of recurrenceClin Cancer Res20071315 Pt 14429443417671126
   PubMed Web of Science ®Google Scholar
• BauerKRBrownMCressRDDescriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registryCancer200710991721172817387718
   PubMed Web of Science ®Google Scholar
• LoiblSMullerBMvon MinckwitzGAndrogen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapyBreast Cancer Res Treat2011130247748721837479
   PubMed Web of Science ®Google Scholar
• LehmannBDBauerJAChenXIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest201112172750276721633166
   PubMed Web of Science ®Google Scholar
• HafftyBGYangQReissMLocoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancerJ Clin Oncol200624365652565717116942
   PubMed Web of Science ®Google Scholar
• TanDSMarchioCJonesRLTriple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patientsBreast Cancer Res Treat20081111274417922188
   PubMedGoogle Scholar
• PerouCMSorlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• SorlieTTibshiraniRParkerJRepeated observation of breast tumor subtypes in independent gene expression data setsProc Natl Acad Sci U S A2003100148418842312829800
   PubMed Web of Science ®Google Scholar
• PratAParkerJSKarginovaOPhenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Res2010125R6820813035
   PubMed Web of Science ®Google Scholar
• LehmannBDJovanovicBChenXRefinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selectionPLoS One2016116e015736827310713
   PubMed Web of Science ®Google Scholar
• LehmannBDPietenpolJAIdentification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypesJ Pathol2014232214215024114677
   PubMed Web of Science ®Google Scholar
• RampurwalaMWisinskiKBO’ReganRRole of the androgen receptor in triple-negative breast cancerClin Adv Hematol Oncol201614318619327058032
   PubMed Web of Science ®Google Scholar
• NiMChenYLimETargeting androgen receptor in estrogen receptor-negative breast cancerCancer Cell201120111913121741601
   PubMed Web of Science ®Google Scholar
• LiuYNLiuYLeeHJActivated androgen receptor down-regulates E-cadherin gene expression and promotes tumor metastasisMol Cell Biol200828237096710818794357
   PubMedGoogle Scholar
• NaderiAHughes-DaviesLA functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancerNeoplasia200810654254818516291
   PubMedGoogle Scholar
• WangYRomighTHeXDifferential regulation of PTEN expression by androgen receptor in prostate and breast cancersOncogene201130424327433821532617
   PubMedGoogle Scholar
• PetersAABuchananGRicciardelliCAndrogen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancerCancer Res200969156131614019638585
   PubMedGoogle Scholar
• BartonVND’AmatoNCGordonMAMultiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivoMol Cancer Ther201514376977825713333
   PubMed Web of Science ®Google Scholar
• CochraneDRBernalesSJacobsenBMRole of the androgen receptor in breast cancer and preclinical analysis of enzalutamideBreast Cancer Res2014161R724451109
   PubMed Web of Science ®Google Scholar
• BourdeauVDeschenesJMetivierRGenome-wide identification of high-affinity estrogen response elements in human and mouseMol Endocrinol20041861411142715001666
   PubMedGoogle Scholar
• CarrollJSMeyerCASongJGenome-wide analysis of estrogen receptor binding sitesNat Genet200638111289129717013392
   PubMed Web of Science ®Google Scholar
• LanzinoMDe AmicisFMcPhaulMJEndogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cellsJ Biol Chem200528021204212043015772083
   PubMed Web of Science ®Google Scholar
• AleskandaranyMAAbduljabbarRAshankytyIPrognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysisBreast Cancer Res Treat2016159221522727514395
   PubMed Web of Science ®Google Scholar
• HuRDawoodSHolmesMDAndrogen receptor expression and breast cancer survival in postmenopausal womenClin Cancer Res20111771867187421325075
   PubMed Web of Science ®Google Scholar
• QuQMaoYFeiXCThe impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysisPLoS One2013812e8265024324816
   PubMed Web of Science ®Google Scholar
• Vera-BadilloFETempletonAJde GouveiaPAndrogen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysisJ Natl Cancer Inst20141061djt31924273215
   PubMedGoogle Scholar
• CollinsLCColeKSMarottiJDAndrogen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health StudyMod Pathol201124792493121552212
   PubMed Web of Science ®Google Scholar
• ElebroKBorgquistSSimonssonMCombined androgen and estrogen receptor status in breast cancer: treatment prediction and prognosis in a population-based prospective cohortClin Cancer Res201521163640365025904752
   PubMedGoogle Scholar
• ParkSKooJParkHSExpression of androgen receptors in primary breast cancerAnn Oncol201021348849219887463
   PubMed Web of Science ®Google Scholar
• ParkSKooJSKimMSAndrogen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancersAnn Oncol20112281755176221310761
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAMStemke-HaleKPallaSLAndrogen receptor levels and association with PIK3CA mutations and prognosis in breast cancerClin Cancer Res20091572472247819276248
   PubMed Web of Science ®Google Scholar
• HeJPengRYuanZPrognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarrayMed Oncol201229240641021264529
   PubMed Web of Science ®Google Scholar
• SafarpourDPakneshanSTavassoliFAAndrogen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?Am J Cancer Res20144435336825057438
   PubMed Web of Science ®Google Scholar
• AgoffSNSwansonPELindenHAndrogen receptor expression in estrogen receptor-negative breast cancerAm J Clin Pathol2003120572573114608899
   PubMedGoogle Scholar
• BryanRMMercerRJBennettRCAndrogen receptors in breast cancerCancer19845411243624406498736
   PubMedGoogle Scholar
• CastellanoIAlliaEAccortanzoVAndrogen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancersBreast Cancer Res Treat2010124360761720127405
   PubMed Web of Science ®Google Scholar
• HickeyTERobinsonJLCarrollJSMinireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?Mol Endocrinol20122681252126722745190
   PubMedGoogle Scholar
• LabrieFEl-AlfyMBergerLThe combination of a novel selective estrogen receptor modulator with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women’s health?Endocrinology2003144114700470612960051
   PubMedGoogle Scholar
• MehtaJAsthanaSMandalCCA molecular analysis provides novel insights into androgen receptor signalling in breast cancerPLoS One2015103e012062225781993
   PubMedGoogle Scholar
• McGhanLJMcCulloughAEProtheroeCAAndrogen receptor-positive triple negative breast cancer: a unique breast cancer subtypeAnn Surg Oncol201421236136724046116
   PubMed Web of Science ®Google Scholar
• MrklicIPogorelicZCapkunVExpression of androgen receptors in triple negative breast carcinomasActa Histochem2013115434434823031358
   PubMed Web of Science ®Google Scholar
• SuttonLMCaoDSarodeVDecreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinomaAm J Clin Pathol2012138451151623010705
   PubMed Web of Science ®Google Scholar
• TangDXuSZhangQThe expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancerMed Oncol201229252653321519872
   PubMed Web of Science ®Google Scholar
• CauleyJALucasFLKullerLHElevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancerAnn Intern Med19991304 Pt 127027710068384
   PubMedGoogle Scholar
• RakhaEAEl-SayedMEGreenARPrognostic markers in triple-negative breast cancerCancer20071091253217146782
   PubMed Web of Science ®Google Scholar
• FarmerPBonnefoiHBecetteVIdentification of molecular apocrine breast tumours by microarray analysisOncogene200524294660467115897907
   PubMed Web of Science ®Google Scholar
• MillsAMGottliebCWendrothSPure apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast cancersAm J Surg Pathol20164081109111627259012
   PubMedGoogle Scholar
• WangCPanBZhuHPrognostic value of androgen receptor in triple negative breast cancer: a meta-analysisOncotarget2016729464824689127374089
   PubMedGoogle Scholar
• ParkerJSPetersonACTudorICA novel biomarker may predict clinical activity from enzalutamide in triple-negative breast cancerPoster presented at: 2015 ASCO Annual MeetingMay 29–June 2; 2015Chicago, IL
   Google Scholar
• PratAPerouCMDeconstructing the molecular portraits of breast cancerMol Oncol20115152321147047
   PubMed Web of Science ®Google Scholar
• BastienRRRodriguez-LescureAEbbertMTPAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markersBMC Med Genomics201254423035882
   PubMed Web of Science ®Google Scholar
• PratAAdamoBCheangMCMolecular characterization of basal-like and non-basal-like triple-negative breast cancerOncologist201318212313323404817
   PubMed Web of Science ®Google Scholar
• RingBZHoutDRMorrisSWGeneration of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patientsBMC Cancer20161614326908167
   PubMedGoogle Scholar
• MasudaHBaggerlyKAWangYDifferential response to neo-adjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypesClin Cancer Res201319195533554023948975
   PubMed Web of Science ®Google Scholar
• AsanoYKashiwagiSOnodaNClinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancerBr J Cancer20161141142026757422
   PubMed Web of Science ®Google Scholar
• CortazarPZhangLUntchMPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet2014384993816417224529560
   PubMed Web of Science ®Google Scholar
• RouzierRPerouCMSymmansWFBreast cancer molecular subtypes respond differently to preoperative chemotherapyClin Cancer Res200511165678568516115903
   PubMed Web of Science ®Google Scholar
• ZhuALiYSongWAntiproliferative effect of androgen receptor inhibition in mesenchymal stem-like triple-negative breast cancerCell Physiol Biochem20163831003101426938985
   PubMed Web of Science ®Google Scholar
• WongYCXieBThe role of androgens in mammary carcinogenesisItal J Anat Embryol20011062 Suppl 111112511729946
   PubMedGoogle Scholar
• FurrBJValcacciaBCurryBICI 176,334: a novel non-steroidal, peripherally selective antiandrogenJ Endocrinol19871133R7R93625091
   PubMed Web of Science ®Google Scholar
• GucalpATolaneySIsakoffSJPhase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancerClin Cancer Res201319195505551223965901
   PubMed Web of Science ®Google Scholar
• SzeleiJJimenezJSotoAMAndrogen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptorEndocrinology19971384140614129075695
   PubMedGoogle Scholar
• Toth-FejelSCheekJCalhounKEstrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic toolArch Surg20041391505414718276
   PubMedGoogle Scholar
• Arce-SalinasCRiesco-MartinezMCHannaWComplete response of metastatic androgen receptor-positive breast cancer to bicalutamide: case report and review of the literatureJ Clin Oncol2016344e21e2424888812
   PubMed Web of Science ®Google Scholar
• WirthMPHakenbergOWFroehnerMAntiandrogens in the treatment of prostate cancerEur Urol2007512306313 discussion 1417007995
   PubMed Web of Science ®Google Scholar
• AndersonJThe role of antiandrogen monotherapy in the treatment of prostate cancerBJU Int200391545546112603397
   PubMedGoogle Scholar
• PilepichMVWinterKJohnMJPhase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostateInt J Radiat Oncol, Biol, Phys20015051243125211483335
   PubMed Web of Science ®Google Scholar
• BaekSHOhgiKANelsonCALigand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cellsProc Natl Acad Sci U S A200610393100310516492776
   PubMedGoogle Scholar
• ChengSBrzostekSLeeSRInhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressorMol Endocrinol20021671492150112089345
   PubMedGoogle Scholar
• TranCOukSCleggNJDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancerScience2009324592878779019359544
   PubMed Web of Science ®Google Scholar
• BedoyaDJMitsiadesNClinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directionsOnco Targets Ther2013691823319868
   PubMed Web of Science ®Google Scholar
• AntonarakisESLuCWangHAR-V7 and resistance to enzalutamide and abiraterone in prostate cancerN Engl J Med2014371111028103825184630
   PubMed Web of Science ®Google Scholar
• AzadAAEiglBJMurrayRNEfficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patientsEur Urol2015671232925018038
   PubMed Web of Science ®Google Scholar
• RomanelAGasi TandefeltDConteducaVPlasma AR and abiraterone-resistant prostate cancerSci Transl Med20157312312re10
   PubMed Web of Science ®Google Scholar
• SalviSCasadioVConteducaVCirculating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abirateroneBr J Cancer2015112101717172425897673
   PubMed Web of Science ®Google Scholar
• KwilasARArdianiAGameiroSRAndrogen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerinOncotarget20167172349823451127015557
   PubMedGoogle Scholar
• ArdianiAFarsaciBRogersCJCombination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer modelClin Cancer Res201319226205621824048332
   PubMed Web of Science ®Google Scholar
• TrainaTMillerKYardleyDResults from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)J Clin Oncol201533suppl abstr 1003
   PubMedGoogle Scholar
• BonnefoiHGrelletyTTredanOA phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)Ann Oncol201627581281827052658
   PubMed Web of Science ®Google Scholar
• FryDWHarveyPJKellerPRSpecific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenograftsMol Cancer Ther20043111427143815542782
   PubMed Web of Science ®Google Scholar
• AsgharUHerrera-AbreuMTCuttsRIdentification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibitionJ Clin Oncol201533suppl abstr 11098
   Google Scholar
• TrereDBrighentiEDonatiGHigh prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapyAnn Oncol200920111818182319556322
   PubMed Web of Science ®Google Scholar
• Cuenca-LopezMDMonteroJCMoralesJCPhospho-kinase profile of triple negative breast cancer and androgen receptor signalingBMC Cancer20141430224779793
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• LehmannBDBauerJASchaferJMPIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitorsBreast Cancer Res201416440625103565
   PubMed Web of Science ®Google Scholar
• RoblesAJCaiSCichewiczRHSelective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancerBreast Cancer Res Treat2016157347548827255535
   PubMedGoogle Scholar
• DehmSMSchmidtLJHeemersHVSplicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistanceCancer Res200868135469547718593950
   PubMed Web of Science ®Google Scholar
• VisakorpiTHyytinenEKoivistoPIn vivo amplification of the androgen receptor gene and progression of human prostate cancerNat Genet1995944014067795646
   PubMed Web of Science ®Google Scholar
• HickeyTEIrvineCMDvingeHExpression of androgen receptor splice variants in clinical breast cancersOncotarget2015642447284474426554309
   PubMedGoogle Scholar
• FerraldeschiRWeltiJPowersMVSecond-generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cellsCancer Res20167692731274227197266
   PubMed Web of Science ®Google Scholar
• WangJZouJXXueXROR-gamma drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancerNat Med201622548849627019329
   PubMed Web of Science ®Google Scholar
• KallergiGAgelakiSMarkomanolakiHActivation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cellsCell Physiol Biochem200720697798617982280
   PubMedGoogle Scholar
• KampaMNifliAPCharalampopoulosIOpposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosisExp Cell Res20053071415115922725
   PubMedGoogle Scholar
• PelekanouVNotasGSanidasETestosterone membrane-initiated action in breast cancer cells: interaction with the androgen signaling pathway and EPORMol Oncol20104213514920189893
   PubMedGoogle Scholar
• KousteniSBellidoTPlotkinLINongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activityCell2001104571973011257226
   PubMed Web of Science ®Google Scholar
• MigliaccioACastoriaGDi DomenicoMSteroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferationEMBO J200019205406541711032808
   PubMedGoogle Scholar
• AlevizopoulosKBacopoulosNPapadopoulouNPreclinical studies of MDX-12C, a selective membrane androgen receptor ligand with activity in prostate cancerJ Clin Oncol20082615 suppl abstr 14549
   Google Scholar
• MalaguarneraRSaccoAMorcavalloAMetformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signalingEndocrinology201415541207122124437490
   PubMedGoogle Scholar
• ChuangKHAltuwaijriSLiGNeutropenia with impaired host defense against microbial infection in mice lacking androgen receptorJ Exp Med200920651181119919414555
   PubMedGoogle Scholar
• ViselliSMStanzialeSShultsKCastration alters peripheral immune function in normal male miceImmunology19958423373427751013
   PubMed Web of Science ®Google Scholar
• ChopraDPMenardREJanuszewskiJTNF-alpha-mediated apoptosis in normal human prostate epithelial cells and tumor cell linesCancer Lett2004203214515414732222
   PubMedGoogle Scholar
• HaradaSKellerETFujimotoNLong-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cellsProstate200146431932611241555
   PubMed Web of Science ®Google Scholar
• ChenTWangLHFarrarWLInterleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cellsCancer Res20006082132213510786674
   PubMed Web of Science ®Google Scholar
• HobischAEderIEPutzTInterleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptorCancer Res19985820464046459788616
   PubMed Web of Science ®Google Scholar
• LinDLWhitneyMCYaoZInterleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expressionClin Cancer Res2001761773178111410519
   PubMed Web of Science ®Google Scholar
• AarnisaloPPalvimoJJJanneOACREB-binding protein in androgen receptor-mediated signalingProc Natl Acad Sci U S A1998955212221279482849
   PubMed Web of Science ®Google Scholar
• CinarBDe BenedettiAFreemanMRPost-transcriptional regulation of the androgen receptor by mammalian target of rapamycinCancer Res20056572547255315805247
   PubMedGoogle Scholar
• MatsudaTJunichoAYamamotoTCross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cellsBiochem Biophys Res Commun2001283117918711322786
   PubMedGoogle Scholar
• NakajimaYDelliPizziAMMallouhCTNF-mediated cytotoxicity and resistance in human prostate cancer cell linesProstate19962952963028899002
   PubMedGoogle Scholar
• UedaTBruchovskyNSadarMDActivation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathwaysJ Biol Chem200227797076708511751884
   PubMed Web of Science ®Google Scholar
• Sanchez-HernandezMChaves-PozoECabasITestosterone implants modify the steroid hormone balance and the gonadal physiology of gilthead seabream (Sparus aurata L.) malesJ Steroid Biochem Mol Biol201313818319423743364
   PubMedGoogle Scholar
• ParkerJPetersonATudorIA novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBCJ Clin Oncol20153315 suppl abstr 1083
   Google Scholar
• CarterACSedranksNKelleyRMDiethylstilbestrol: recommended dosages for different categories of breast cancer patientsJAMA19772371920792085576887
   PubMedGoogle Scholar
• GockermanJPSpremulliENRaneyMLoganTRandomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trialCancer Treat Rep19867010119912033530447
   PubMedGoogle Scholar